ToeFX Light Therapy for Chronic Venous Leg Ulcers
Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Ahmed Kayssi, MD MSc FRCSC
- Numéro de téléphone: (416) 691-2030
- E-mail: ahmed.kayssi@sunnybrook.ca
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M4L 3Y3
- East Toronto Vascular Clinic
-
Contact:
- Ahmed Kayssi, MD MSc FRCSC
- Numéro de téléphone: (416) 691-2030
- E-mail: ahmed.kayssi@sunnybrook.ca
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18 years or older
- Able to attend weekly visits for up to 12 weeks
- Chronic venous leg ulcer (CEAP C6) of the lower extremity
- Ulcer duration of 4 weeks or more
- Ulcer size between 1 cm² and 20 cm² at baseline
- Receiving standard-of-care compression therapy, or eligible to initiate it
- Able to provide informed consent and comply with study procedures
Exclusion Criteria:
- Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
- Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
- Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
- Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
- Heavy exudate requiring negative-pressure wound therapy
- Known photosensitivity or allergy to methylene blue or light-based therapies
- Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
- Pregnancy or lactation
- Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Participation in another interventional study within 30 days of screening
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Faisabilité de l'appareil
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: ToeFX Treatment
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure |
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment adherence
Délai: Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions |
Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
|
Safety: Adverse Events
Délai: Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs |
Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent Change in Wound Area From Baseline
Délai: Baseline, week 4, week 8, and week 12
|
Percent change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
|
Complete wound epithelialization
Délai: 12 weeks
|
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician |
12 weeks
|
|
Time to complete wound healing
Délai: 12 weeks
|
Time (days) from baseline to complete epithelialization |
12 weeks
|
|
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Délai: Baseline to 12 weeks/ end of treatment
|
Change in wound bed characteristics measured using the BWAT |
Baseline to 12 weeks/ end of treatment
|
|
Change in pain score
Délai: Baseline to 12 weeks/ end of treatment
|
Change in pain score (0-10 Numeric Rating Scale) |
Baseline to 12 weeks/ end of treatment
|
|
Change in health-related quality of life
Délai: 12 weeks/ end of treatment
|
Change in EQ-5D-5L score |
12 weeks/ end of treatment
|
|
Patient satisfaction
Délai: 12 weeks/ end of treatment
|
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire |
12 weeks/ end of treatment
|
|
Clinician feasibility
Délai: 14 weeks or earlier if wound healing
|
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow |
14 weeks or earlier if wound healing
|
|
Absolute Change in Wound Area From Baseline
Délai: Baseline, week 4, week 8, and week 12
|
Absolute change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- PRO04244160_ToeFX
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .